Damora Therapeutics Statistics
Total Valuation
DMRA has a market cap or net worth of $1.47 billion. The enterprise value is $939.76 million.
| Market Cap | 1.47B |
| Enterprise Value | 939.76M |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DMRA has 61.90 million shares outstanding. The number of shares has increased by 2,895.78% in one year.
| Current Share Class | 61.74M |
| Shares Outstanding | 61.90M |
| Shares Change (YoY) | +2,895.78% |
| Shares Change (QoQ) | +1.13% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 79.42% |
| Float | 41.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.01 |
| P/TBV Ratio | 4.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.80, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.80 |
| Quick Ratio | 14.75 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -115.80% and return on invested capital (ROIC) is -32.20%.
| Return on Equity (ROE) | -115.80% |
| Return on Assets (ROA) | -29.92% |
| Return on Invested Capital (ROIC) | -32.20% |
| Return on Capital Employed (ROCE) | -26.18% |
| Weighted Average Cost of Capital (WACC) | 12.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$37.55M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DMRA has paid $341,000 in taxes.
| Income Tax | 341,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +298.99% in the last 52 weeks. The beta is 1.51, so DMRA's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +298.99% |
| 50-Day Moving Average | 22.72 |
| 200-Day Moving Average | 25.54 |
| Relative Strength Index (RSI) | 60.18 |
| Average Volume (20 Days) | 447,698 |
Short Selling Information
The latest short interest is 5.15 million, so 8.32% of the outstanding shares have been sold short.
| Short Interest | 5.15M |
| Short Previous Month | 4.73M |
| Short % of Shares Out | 8.32% |
| Short % of Float | 12.40% |
| Short Ratio (days to cover) | 6.65 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -130.05M |
| Pretax Income | -291.34M |
| Net Income | -262.87M |
| EBITDA | -130.03M |
| EBIT | -130.05M |
| Earnings Per Share (EPS) | -$6.64 |
Balance Sheet
The company has $528.48 million in cash and $1.10 million in debt, with a net cash position of $527.38 million or $8.52 per share.
| Cash & Cash Equivalents | 528.48M |
| Total Debt | 1.10M |
| Net Cash | 527.38M |
| Net Cash Per Share | $8.52 |
| Equity (Book Value) | 495.76M |
| Book Value Per Share | 5.91 |
| Working Capital | 495.43M |
Cash Flow
| Operating Cash Flow | -59.13M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 22,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -59.13M |
| FCF Per Share | -$0.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2,895.78% |
| Shareholder Yield | n/a |
| Earnings Yield | -28.02% |
| FCF Yield | -4.03% |
Analyst Forecast
The average price target for DMRA is $46.89, which is 97.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.89 |
| Price Target Difference | 97.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 30, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Aug 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |